Clarify Pharma PLC Result of Annual General Meeting (2898N)

TIDMPSYC

RNS Number : 2898N

Clarify Pharma PLC

30 May 2022

Press Release

30 May 2022

Clarify Pharma PLC

("Clarify Pharma" or "the Company")

Result of Annual General Meeting

Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.

For further information please contact:

 
 Clarify Pharma 
 Jon Bixby                             via Tancredi +44 207 887 7633 
  Executive Chairman 
                                      ------------------------------ 
 First Sentinel 
                                      ------------------------------ 
 Corporate Adviser 
  Brian Stockbridge                    +44 7876 888 011 
                                      ------------------------------ 
 Tennyson Securities 
                                      ------------------------------ 
 Corporate Broker 
  Peter Krens                          +44 207 186 9030 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
                                      ------------------------------ 
 Media Relations 
  Catrina Daly 
  Emma Hodges 
  Salamander Davoudi                     +44 7727 153 868 
                                         +44 7861 995 628 
  clarifypharma@tancredigroup.com        +44 7957 549 906 
                                      ------------------------------

About Clarify Pharma PLC:

Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation. www.clarifypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXURRVRUKUVOAR

(END) Dow Jones Newswires

May 30, 2022 11:27 ET (15:27 GMT)

Clarify Pharma (AQSE:PSYC)
過去株価チャート
から 4 2024 まで 5 2024